Treatment of neurally mediated reflex syncope

Cardiol Clin. 2013 Feb;31(1):123-9. doi: 10.1016/j.ccl.2012.10.007.

Abstract

Neurally mediated reflex syncope, more commonly known as vasovagal syncope (VVS), remains the most common cause of transient loss of consciousness and syncope in all age groups. Most evidence assessing treatment of VVS derived from randomized clinical trials is limited. Multiple modalities of both nonpharmacologic and pharmacologic strategies have been tested, with conflicting results. The treatment of VVS has been directed toward interventions that interrupt the reflex response at different levels, hypothetically preventing the onset of syncope. This article reviews the available evidence of the different nonpharmacologic and pharmacologic therapies available for the treatment of recurrent VVS.

Publication types

  • Review

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use
  • Adrenergic beta-Antagonists / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Counseling
  • Fludrocortisone / therapeutic use
  • Fluid Therapy / methods
  • Humans
  • Hypotension, Orthostatic / prevention & control
  • Patient Education as Topic
  • Plasma Substitutes / therapeutic use
  • Posture
  • Recurrence
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Sodium Chloride, Dietary / administration & dosage
  • Syncope, Vasovagal / therapy*

Substances

  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Anti-Inflammatory Agents
  • Plasma Substitutes
  • Serotonin Uptake Inhibitors
  • Sodium Chloride, Dietary
  • Fludrocortisone